

**Table 1: Baseline characteristics in each arm**

	<b>PRP N=116</b>	<b>Aflibercept N=116</b>
<b>Mean (SD) age</b>	50.8 (13.2)	51.5 (14.6)
<b>Women % (n)</b>	38% (44)	28% (33)
<b>Diabetes Mellitus % (n)</b> Type I Type II	44% (51) 56% (65)	47% (54) 53% (62)
<b>Medication % (n)</b> Insulin only Oral hypoglycaemic agents only Insulin and oral hypoglycaemic agents Diet controlled	46% (53) 21% (24) 34% (39) 0% (0)	53% (61) 22% (26) 25% (29) 0% (0)
<b>Best corrected visual acuity % (n)</b> 54-69 ≥70 ETDRS letters	9% (11) 91% (105)	9% (10) 91% (106)
<b>Lens status (study eye) % (n)</b> Clear lens Visually insignificant Cataract Visually significant Cataract Pseudophakia	69% (80) 22% (26) 0% (0) 9% (10)	59% (68) 32% (37) 0% (0) 9% (10)
<b>Macular oedema (study eye) % (n)</b> No macular oedema Non-central macular oedema Central macular oedema	75% (87) 24% (28) 1% (1)	76% (87) 23% (27) 1% (1)
<b>Mean (SD) Central subfield thickness</b>	271.6 (28.1)	275.3 (30.9) <sup>1</sup>
<b>Mean (SD) total volume (mm<sup>3</sup>)</b>	8.94 (0.88)	8.99 (1.09) <sup>1</sup>
<b>Proliferative Diabetic Retinopathy % (n)</b> Naïve Previously treated active PDR Previous anti-VEGF therapy Previous intravitreal steroid therapy	54% (63) 46% (53) 4% (5) 0% (0)	52% (60) 48% (56) 5% (6) 1% (1)
<b>HbA1C % (n)</b> Below 8% (below 63.90 mmol/mol) 8% to 10% (63.90 mmol/mol to 85.8 mmol/mol) Above 10% (above 85.81 mmol/mol)	38% (44) 41% (48) 21% (24)	35% (41) 44% (51) 21% (24)
<b>Blood pressure (Diastolic) % (n)</b> ≤90mmHg >90mmHg	88% (102) 12% (14)	87% (101) 13% (15)

<sup>1</sup> The Optical Coherence Tomography (OCT) medical imaging was not done for one participant (withdrew at baseline).